Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

Core Insights - The long-term efficacy and safety data from the ATTRibute-CM open-label extension trial demonstrate sustained clinical benefits of acoramidis in patients with ATTR-CM through Month 54, including significant reductions in all-cause and cardiovascular mortality [1][2][3] Efficacy and Safety Data - Acoramidis treatment resulted in a 44.7% reduction in all-cause mortality (ACM) and a 49.3% reduction in cardiovascular mortality (CVM) compared to placebo, marking the earliest timepoint in an open-label extension with such risk reduction [1][3] - The treatment mitigated the rise in NT-proBNP levels through Month 54, an effect not previously observed with disease-modifying treatments [1][3] - Continuous acoramidis treatment maintained heart failure-related quality of life scores (KCCQ-OS), indicating sustained improvements in both duration and quality of life for patients with ATTR-CM [1][3] Treatment Patterns and Patient Preferences - A real-world survey indicated that over half of physicians were not fully satisfied with current treatment options for ATTR-CM, and more than one-third of patients did not receive any treatment [4] - Patients expressed a preference for oral therapy, highlighting unmet treatment needs and the importance of shared decision-making in therapy selection [4] Regulatory Approvals - Acoramidis is approved as Attruby by the U.S. FDA and as BEYONTTRA by various European and Japanese regulatory agencies, with all labels specifying near-complete stabilization of TTR [4]